Drug Trial Radar · NCT07604324
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
63
Planned (sponsor's estimate)
Start
Jun 2, 2026
Primary completion
Jan 27, 2028
Study completion Jan 28, 2028
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
Conditions
- Dermatitis, Atopic
Interventions
DCY636Drug
Participants will receive DCY636
PlaceboDrug
Participants will receive Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1-Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 202 days
- Part 2-Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 301 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Fukuoka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.